| Company | Product | Indication | Details | Date announced |
Clinical trials disrupted: 442 | ||||
| 89bio Inc., of San Francisco | BIO89-100 | Nonalcoholic steatohepatitis | Initiation of phase IIb trial of the FGF receptor agonist now expected in first half of 2021, delayed from first half of 2020, due to COVID-19 pandemic | 4/13/20 |
| AB Science SA, of Paris | Masitinib | Amyotrophic lateral sclerosis | FDA cleared the IND for a phase III study (AB19001); confirmatory phase III study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months; mastinib is a selective tyrosine kinase inhibitor | 3/31/20 |
| AB Science SA, of Paris | Masitinib | Mastocytosis | Confirmatory phase III study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months; mastinib is a selective tyrosine kinase inhibitor | 4/7/20 |
| Actelion Ltd., of Allschwil, Switzerland | Uptravi (selexipag) | Pulmonary arterial hypertension | Study in healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Actelion Ltd., of Allschwil, Switzerland | Uptravi (selexipag) | Pulmonary arterial hypertension | Screening in study to confirm doses in children with PAH on hold due to COVID-19 | 5/12/20 |
| Actelion Ltd., of Allschwil, Switzerland | Uptravi (selexipag) | Chronic thromboembolic pulmonary hypertension | Screening temporarily halted in Select study due to COVID-19 | 5/13/20 |
| Addex Therapeutics Ltd., of Geneva | Dirpaglurant | Parkinson's disease | Ready to begin pivotal phase IIb/III study in patients with levodopa-induced dyskinesia as soon as the COVID-19 pandemic is over; dosing first patient in second half of 2020 will result in data in the second quarter of 2022; dipraglurant is a metabotropic glutamate receptor 5 antagonist | 4/8/20 |
| Addex Therapeutics, of Geneva | Dipraglurant | Levodopa-induced dyskinesia in patients with Parkinson's disease | Postponing the start of the registrational efficacy and safety trial, Study 301, as the intended patient population is among the highest risk category for severe illness and death associated with COVID-19; dipraglurant is a novel orally available mGlu5 NAM | 3/18/20 |
| Adial Pharmaceuticals Inc., of Charlottesville, Va. | AD-04 | Alcohol use disorder | Modifying its pivotal phase III trial to protect patients from COVID-19 by reducing the number of in-person visits to clinical sites and using tele-medicine behavioral treatments and assessments | 3/17/20 |
| Aeglea Biotherapeutics Inc., of Austin, Texas | Pegzilarginase | Arginase 1 deficiency | Disclosed in SEC filing that COVID-19 has created limited access environment, impacting the ability for some sites in Peace study to schedule and complete initial screening visits; company now expects to complete enrollment by end of March 2021 and anticipates top-line data in fourth quarter of 2021; to date, 22 patients (75%) have been enrolled | 1/5/21 |
| Agios Pharmaceuticals Inc., of Cambridge, Mass. | AG-270 | Non-small-cell lung and pancreatic cancers | Enrollment slowed due to COVID-19; go/no-go decision still expected no later than 2022 | 4/30/20 |
| Agios Pharmaceuticals Inc., of Cambridge, Mass. | Mitapivat | Sickle cell disease | Enrollment paused due to COVID-19 | 4/30/20 |
| Agios Pharmaceuticals Inc., of Cambridge, Mass. | Tibsovo (ivosidenib) | Myelodysplastic syndrome | Enrollment completion now expected in 2021 vs. previous guidance of end of 2020, due to COVID-19-related delays | 4/30/20 |
| Agios Pharmaceuticals Inc., of Cambridge, Mass. | Vorasidenib | Low-grade glioma | Enrollment in Indigo study slowed due to COVID-19 | 4/30/20 |
| Aldeyra Therapeutics Inc., of Lexington, Mass. | ADX-2191 | Proliferative vitreoretinopathy | Patient enrollment in part 1 of adaptive Guard trial for prevention of PVR significantly delayed due to lack of clinical site availability and staffing resulting from COVID-19 | 5/7/20 |
| Alexion Pharmaceuticals Inc., of Boston | ALXN-1830 | Warm autoimmune hemolytic anemia | Study stopped due to COVID-19, as WAIHA patients may be at higher risk of contracting disease based on standard-of-care treatments | 5/13/20 |
| Alexion Pharmaceuticals Inc., of Boston | Strensiq (asfotase alfa) | Hypophosphatasia | Study withdrawn after portfolio review and in light of COVID-19 pandemic | 6/1/20 |
| Alligator Bioscience AB, of Lund, Sweden | ATOR-1015 | Metastatic cancer | Temporarily halted recruitment of new patients due to COVID-19 | 4/1/20 |
| Alligator Bioscience AB, of Lund, Sweden | ATOR-1017 | Metastatic cancer | Temporarily halted recruitment of new patients due to COVID-19 | 4/1/20 |
| AM Pharma BV, Utrecht, the Netherlands | Recap | Sepsis-associated acute kidney injury | While current hospital resources are focused on COVID-19, AM Pharma intends to move into the phase III trial as soon as circumstances allow | 3/31/20 |
| Amag Pharmaceuticals Inc., of Waltham, Mass. | AMAG-423 | Pre-eclampsia | Site initiation and enrollment in phase IIb/IIIa trial of the ovine antidigoxin polyclonal antibody fragment expected to be delayed by COVID-19 pandemic | 4/16/20 |
| Amag Pharmaceuticals Inc., of Waltham, Mass. | Ciraparantag | Anticoagulant overdose | Site initiation and enrollment in phase IIb trial of the factor IIa/Xa modulator in healthy volunteers expected to be delayed by COVID-19 pandemic | 4/16/20 |
| Aprea Therapeutics Inc., of Boston | APR-246 | HMA-naïve TP53 mutant myelodysplastic syndromes | Company has observed a decrease in patient screening and enrollment in the phase III trial as a result of COVID-19 | 3/26/20 |
| Aptinyx Inc., of Evanston, Ill. | NYX-2925 | Diabetic peripheral neuropathy | Restarted recruitment and screening following a suspension due to the COVID-19 pandemic | 1/4/21 |
| Argenx NV, of Breda, the Netherlands | Cusatuzumab (ARGX-110) | Acute myeloid leukemia | Partner Janssen Pharmaceuticals paused enrollment of pivotal Culminate trial, testing combination with azacitidine in newly diagnosed elderly patients unfit for intensive chemotherapy, due to COVID-19 | 5/14/20 |
| Aridis Pharmaceuticals Inc., of San Jose, Calif. | AR-301 (tosatoxumab) | Ventilator-associated pneumonia | Enrollment and site activation affected by COVID-19 pandemic; interim data of the human IgG1 monoclonal antibody provisionally expected in second half of 2020 and top-line data in second half of 2021 | 4/9/20 |
| Ark Biosciences Inc., of Shanghai | Ziresovir; AK-3280 | Respiratory syncytial virus; idiopathic pulmonary fibrosis | Ark CEO said the company had to pause some of its clinical studies because research associates could not get to the hospitals due to the COVID-19 pandemic | 3/27/20 |
| Arrowhead Pharmaceuticals Inc., of Pasadena, Calif. | ARO-AAT | Alpha-1 liver disease | Pausing new patient screening for at least a four-week period in the Sequoia and Aroaat2002 studies as many patients have compromised lung function and/or impaired liver function and are at increased risk for COVID-19; patients already enrolled will continue in the study as per the protocol, with options including home healthcare visits and the use of local laboratories; ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin protein | 3/17/20 |
| Aslan Pharmaceuticals Ltd., of Singapore | ASLAN-004 | Atopic dermatitis | Recruitment of the IL-13/IL-4 receptor antagonist in multiple ascending-dose study enrolling adults with moderate to severe disease paused due to COVID-19 pandemic; screening expected to resume in May 2020, with interim unblinded data still expected to report in 2020 | 4/13/20 |
| Astellas Pharma Inc., of Tokyo | ASP-1617 | Unspecified | Study assessing food effect in healthy adult non-Asian and Japanese subjects suspended due to COVID-19 | 5/15/20 |
| Astellas Pharma Inc., of Tokyo | ASP-2390 | House dust mite allergy | Study suspended due to COVID-19 | 5/15/20 |
| Astellas Pharma Inc., of Tokyo | Fezolinetant | Unspecified | Trial assessing bioequivalence of fezolinetant formulations in postmenopausal women suspended due to COVID-19 | 5/15/20 |
| Astex Pharmaceuticals Inc., of Pleasanton, Calif., a subsidiary of Otsuka Pharmaceutical Co. Ltd., and Forma Therapeutics Inc., of Watertown, Mass. | ASTX-727 and FT-2102 | Recurrent/refractory myelodysplastic syndrome of acute myeloid leukemia | Phase I/II study in patients with IDHI-mutated disease paused due to COVID-19 | 5/20/20 |
| Astrazeneca plc, of Cambridge, U.K. | AZD-9977 | Heart failure with preserved ejection fraction | Study to compare effect of AZD-9977 and spironolactone on serum potassium in HFpEF patients terminated; attendance at study sites carries risk of COVID-19 infection, and non-attendance deemed unacceptable patient safety risk | 5/1/20 |
| Astrazeneca plc, of Cambridge, U.K. | Budesonide and Formoterol via two different inhalers | Chronic obstructive pulmonary disease | Phase III trial put on hold due to the COVID-19 pandemic | 4/8/20 |
| Astrazeneca plc, of Cambridge, U.K. | Olaparib | Prostate cancer | Phase II study temporarily suspended due to COVID-19 | 3/31/20 |
| Astrazeneca plc, of Cambridge, U.K. | Vinorelbine | Advanced solid tumors | Suspended phase I/II Movie trial testing combination with anti-PD-L1/anti-CTLA4 immunotherapy due to COVID-19 | 4/20/20 |
| Atara Biotherapeutics Inc., of South San Francisco | ATA-188 | Progressive multiple sclerosis | Temporarily paused screening and enrollment of patients in phase Ib study due to COVID-19; company expects pause to be limited and plans to initiate enrollment in second or third quarter of 2020 | 5/7/20 |
| Atara Biotherapeutics Inc., of South San Francisco | ATA-188 | Multiple sclerosis | Monitoring of enrolled participants and retreatment in open-label extension of phase Ia continue; screening and enrollment of phase Ib participants paused due to COVID-19 pandemic; Autologous cytotoxic T-lymphocyte therapy | 4/2/20 |
| Auris Medical Holding Ltd., of Hamilton, Bermuda | AM-125 | Acute peripheral vertigo | Resumed enrollment in study that was paused due to COVID-19; interim analysis expected in the third quarter of 2020 | 5/26/20 |
| Auris Medical Holding Ltd., of Hamilton, Bermuda | AM-125 (betahistine, intranasal) | Acute peripheral vertigo | Enrollment in Travers phase II trial halted in March 2020 after sites reduced or suspended research activities due to COVID-19 pandemic; interim analysis following part A of trial now expected no sooner than third quarter of 2020 | 4/6/20 |
| Autifony Therapeutics Ltd., of Stevenage, U.K. | AUT0-0201 | Schizophrenia; hearing disorders | Single and multiple ascending-dose trial underway in U.K. in healthy volunteers suspended temporarily due to COVID-19 pandemic | 5/4/20 |
| Aveo Oncology Inc., of Cambridge, Mass. | Ficlatuzumab | Relapsed/refractory acute myeloid leukemia | CyFi-2 phase II study discontinued due to COVID-19 pandemic | 3/30/20 |
| Avrobio Inc., of Cambridge, Mass. | AVR-RD-02 | Gaucher disease | First patient enrolled and completed apheresis in phase I/II study, and dosing is anticipated for the second quarter but is dependent on when the clinical site allows; subsequent new enrollment timelines impacted by COVID-19 | 5/7/20 |
| Avrobio Inc., of Cambridge, Mass. | AVR-RD-04 | Cystinosis | Patient identification activities ongoing in phase I/II study, though certain data collection temporarily delayed due to COVID-19 | 5/7/20 |
| Axsome Therapeutics Inc., of New York | AXS-05 (dextromethorphan/bupropion) | Alzheimer's disease agitation | Accelerating completion of the Advance-1 phase II/III trial of the oral NMDA receptor antagonist; randomization have concluded and trial participation is ending to ensure patient safety during COVID-19; topline results are expected early in the second quarter, instead of the third quarter of 2020 | 3/20/20 |
| Azevan Pharmaceuticals Inc., of Bethlehem, Pa. | SRX-246 | Post traumatic stress disorder | Study suspended due to COVID-19 | 6/18/20 |
| Bayer AG, of Leverkusen, Germany | Azelastine hydrochloride (BAYR-9258) | Allergic rhinitis | Suspended due to COVID-19 | 5/18/20 |
| Bellicum Pharmaceuticals Inc., of Houston | Rivogenlecleucel donor lymphocyte immunotherapy | Recurrent blood cancers after stem cell transplant | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/10/20 |
| Bellus Health Inc., of Laval, Quebec | BLU-5397 | Unexplained or refractory chronic cough | Terminated due to impact of COVID-19 on trial activities | 4/29/20 |
| Bellus Health Inc., of Laval, Quebec | BLU-5937 | Refractory chronic cough | Completed dosing of 52 patients in the Relief study of the P2X3 receptor antagonist; 16 patients dropped out of the study, including 13 due to COVID-19 pandemic or early termination of the trial; data expected in mid-2020 | 4/7/20 |
| Belx Bio-Pharmaceutical (Taiwan) Corp., of Taiwan | Bel-X-HG | Advanced cancer | Terminated in light of ongoing COVID-19 pandemic, which resulted in difficulty with patient enrollment | 6/1/20 |
| Bergenbio ASA, of Bergen, Norway | Bemcentinib | Lung cancer and leukemia | Measures taken to reduce the spread of COVID-19 are expected to impact patient recruitment in Bergenbio's clinical studies, including the phase II trial, and will extend previously anticipated timelines | 3/27/20 |
| Bicycle Therapeutics plc, of Cambridge, U.K. | BT-1718 | Solid tumors | Enrollment of new patients in phase IIa portion of trial at Cancer Research UK sites paused due to the COVID-19 pandemic | 5/7/20 |
| Bicycle Therapeutics plc, of Cambridge, U.K. | BT-8009 | Advanced solid tumors associated with Nectin-4 expression | Plans to start a phase I clinical trial of the peptide-toxin conjugate targeting Nectin-4 this year, subject to impact of COVID-19 pandemic | 4/7/20 |
| Bioarctic AB, of Stockholm, and Eisai Co. Ltd., of Tokyo | Lecanemab (BAN-2401) | Alzheimer's disease | Target enrollment number increased by about 200 in pivotal Clarity AD trial in people with early disease to ensure robust dataset and mitigate potential impact of missed doses due to COVID-19 pandemic; data readout still expected by September 2022 | 2/3/21 |
| Biogen Inc., of Cambridge, Mass. | BIIB-067 (tofersen) | Motor neuron disease | Healthy volunteer study testing microdose of radiolabeled BIIB-067 (99mTc-MAG3-BIIB067) co-administered with BIIB-067 on hold due to COVID-19 | 5/12/20 |
| Bionic Sight LLC, of New York | BS-01 (optogenetic gene therapy) | Retinitis pigmentosa | First participant dosed in phase I/II trial assessing effectiveness to detect light, motion and shape/object recognition; application of therapy to subsequent participants postponed due to COVID-19 pandemic, with enrollment set to resume in second half of 2020 | 6/16/20 |
| Biontech SE, of Mainz, Germany | HPV anti-CD40 RNA vaccine | HPV16+ head and neck cancer | Phase I study suspended due to COVID-19 | 3/26/20 |
| Biontech SE, of Mainz, Germany | NEO-PV-01 | Advanced melanoma | Study testing product, either with APX-005M (Apexigen Therapeutics Inc.) or Opdivo (nivolumab, Bristol Myers Squibb Co.) in patients with advanced or metastatic disease closed due to historically slow enrollment compounded by COVID-19 pandemic | 9/4/20 |
| Blade Therapeutics Inc., of South San Francisco | BLD-2660 | Idiopathic pulmonary fibrosis | Suspended due to concerns for patient safety during COVID-19 crisis | 9/3/20 |
| Blueberry Therapeutics Ltd., of Macclesfield, U.K. | BB-2603 | Onychomycosis | Study paused due to COVID-19 pandemic impact | 11/10/20 |
| Bluebird Bio Inc., of Cambridge, Mass. | bb-21217 | Multiple myeloma | Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct | 3/26/20 |
| Bluebird Bio Inc., of Cambridge, Mass. | FH-MCVA2TCR autologous T cells | Metastatic or unresectable Merkel cell cancer | Phase I/II study suspended due to COVID-19 | 4/21/20 |
| Bluebird Bio Inc., of Cambridge, Mass. | lenti-D | Cerebral adrenoleukodystrophy | Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct | 3/26/20 |
| Bluebird Bio Inc., of Cambridge, Mass. | Lentiglobin | Beta-thalassemia and sickle cell disease | Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct; rolling BLA submission to the FDA for lentiglobin will not be complete until mid-2021 | 3/26/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Afatinib | Pediatric tumors | Recruitment in phase I/II study temporarily halted due to COVID-19 | 4/21/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1265162 | Healthy subjects | Recruitment of phase I trial discontinued due to COVID-19 | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1265162 | Cystic fibrosis | Study testing use of Respimat inhaler suspended due to COVID-19 | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1265162 delivered by Respimat inhaler | Cystic fibrosis | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1323495 | Healthy subjects | Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1323495 | Healthy subjects | Recruitment of phase I trial discontinued due to COVID-19 | 4/8/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1323495 | Chronic obstructive pulmonary disease; cystic fibrosis | Study designed to investigate the relative bioavailabilities of rosuvastatin and dabigatran given alone and together with BI-1323495 to healthy people suspended due to COVID-19 | 4/24/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1387446 alone or in combination with BI-754091 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-1701963 alone and combined with Trametinib | Solid tumors | Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-409306 | Attenuated psychosis syndrome | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-409306 | Schizophrenia | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-425809 | Schizophrenia | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-425809 | Schizophrenia | Study testing drug in combination with brain training suspended due to COVID-19 | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-474121 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-655130 | Fistulizing Crohn's disease | Recruitment of new subjects temporarily discontinued due to COVID-19 | 4/20/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-685509 | Hepatic impairment | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/9/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-690517 | Diabetic kidney disease | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-706321 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-706321 | Unidentified indication | Study designed to investigate safety, tolerability, pharmacokinetics and bioavailability in healthy people suspended due to COVID-19 | 4/24/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-730357 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/10/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754091 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754091 in combination with other checkpoint inhibitors | Solid tumors | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754091/BI-754111 | Neoplasm | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/9/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754111 | Non-small cell lung cancer or head and neck cancer | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754111 alone or in combination with BI-754091 | Non-small cell lung cancer | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-754132 | Age-related macular degeneration | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-764198 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-836880 | Wet macular degeneration | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-836880 alone and in combination with BI-754091 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-836880 in combination with BI-754091 | Non-small cell lung cancer | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-891065 alone and in combination with BI-754091 | Solid tumors | Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-894416 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-894416 | Asthma | Study designed to investigate safety, tolerability, pharmacokinetics and bioavailability in healthy people suspended due to COVID-19 | 4/24/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-905677 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/6/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-905681 | Neoplasm | Recruitment of phase I trial temporarily discontinued due to COVID-19 | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-905711 | Gastrointestinal cancer | Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-907828 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-907828 in combination with BI-754091 and BI-754111 | Solid tumors | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | BI-907828; BI-754091; BI-754111 | Solid tumors | Suspended due to COVID-19 pandemic | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Idarucizumab | Atrial fibrillation | Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Idarucizumab | Bleeding | Recruitment of new patients who take dabigatran and need emergency surgery or are bleeding suspended due to COVID-19 | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Linagliptin and empagliflozin | Type 2 diabetes | Halted recruitment of new children and adolescents due to COVID-19 | 4/21/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Nintedanib | Idiopathic pulmonary fibrosis | Study in patients for pulmonary rehabilitation IPF suspended due to COVID-19 | 4/21/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Nintedanib | Interstitial lung disease | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Tiotropium + olodaterol | Chronic obstructive pulmonary disease | Recruitment of phase IV trial temporarily paused due to the COVID-19 pandemic | 4/7/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Xentuzumab | Solid tumors | Study aiming to find safe dose in combination with abemaciclib, with or without hormonal therapies, suspended due to COVID-19 | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Xentuzumab in combination with Abemaciclib | Lung and breast cancer | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/22/20 |
| Boehringer Ingelheim GmbH, of Ingelheim, Germany | Xentuzumab plus Everolimus and Exemestane | Hormone receptor positive and HER2-negative breast cancer | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/9/20 |
| Bristol Myers Squibb Co., of New York | Nivolumab plus Relatlimab or Ipilimumab | Metastatic melanoma | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Bristol Myers Squibb Co., of New York | Opdivo (nivolumab) | High-risk human papillomavirus-related head and neck cancer | Study testing combination with radiotherapy and carboplatin/paclitaxel suspended due to COVID-19 | 5/1/20 |
| Bristol Myers Squibb Co., of New York | pTVG-HP and Nivolumab | Non-metastatic PSA-recurrent prostate cancer | Phase II study temporarily suspended due to COVID-19 | 4/1/20 |
| Bristol Myers Squibb Co., of New York | Various drugs | Various indications | Company posted a letter to clinical investigators suspending new site activations for ongoing trials, as of March 20 through April 13 and possibly later; sites for new studies will not be activated globally, and studies involving healthy volunteers should not initiate | 3/20/20 |
| Bristol Myers Squibb Co., of New York and Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson | JNJ-70033093 and Digoxin | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/3/20 |
| Cabaletta Bio Inc., of Philadelphia | DSG3-CAART | Mucosal pemphigus vulgaris | Anticipates a delay in reporting the acute safety data from the first cohort in DesCAARTes trial due to COVID-19 pandemic | 3/30/20 |
| Cadent Therapeutics Inc., of Cambridge, Mass. | CAD-1883 | Spinocerebellar ataxia | Trial initiation delayed due to COVID-19 pandemic | 4/29/20 |
| Cadent Therapeutics, of Cambridge, Mass. | CAD-1883 | Spinocerebellar ataxia | Phase II trial scheduled to start in August 2020 was suspended due to COVID-19 | 4/13/20 |
| Calithera Biosciences Inc., of South San Francisco | CB-280 | Cystic fibrosis | Enrollment of the arginase inhibitor delayed until third quarter of 2020 due to COVID-19 pandemic | 4/14/20 |
| Calithera Biosciences Inc., of South San Francisco | Telaglenastat | Renal cell carcinoma; triple-negative breast cancer | Dose-expansion cohorts in phase I/II combination trial of the glutaminase inhibitor with CDK4/6 inhibitor Ibrance (palbociclib, Pfizer Inc.) and PARP inhibitor Talzenna (talazoparib, Pfizer) paused due to COVID-19 pandemic; enrollment expected to resume in third quarter 2020 | 4/14/20 |
| Calithera Biosciences Inc., of South San Francisco | Telaglenastat | Colorectal cancer; non-small-cell lung cancer | Dose-expansion cohorts in phase I/II combination trial of the glutaminase inhibitor with CDK4/6 inhibitor Ibrance (palbociclib, Pfizer Inc.) in KRAS-mutated disease paused due to COVID-19 pandemic; enrollment expected to resume in third quarter 2020 | 4/14/20 |
| Calithera Biosciences Inc., of South San Francisco | Telaglenastat | Non-small-cell lung cancer | Enrollment of first participant in the phase II Keapsake trial assessing the glutaminase inhibitor in those with NRF2/KEAP1 mutation delayed until third quarter of 2020 due to COVID-19 pandemic; interim data expected in 2021 | 4/14/20 |
| Cassava Sciences Inc., of Austin, Texas | PTI-125 | Alzheimer's disease | Initiated an open-label extension of its phase II, but sites may slow pace of enrollment to minimize risk of exposure to coronavirus | 3/25/20 |
| Catalyst Pharmaceuticals Inc., of Coral Gables, Fla. | Firdapse (amifampridine) | Spinal muscular atrophy type III | Proof-of-concept trial fully recruited and screened but not permitted to start due to Serbian government regulations related to COVID-19 pandemic; top-line data will not be reported by end of second quarter; Firdapse is a potassium channel inhibitor | 4/8/20 |
| Cindome Pharma LLC, a subsidiary of Cincinnati-based Cinrx Pharma LLC | CIN-102 | Diabetic gastroparesis | Terminated due to impact of COVID-19 on trial activities | 5/18/20 |
| Cohbar Inc., of Menlo Park, Calif. | CB4-211 | Nonalcoholic steatohepatitis | Anticipating delays in the completion of the CB4-211 phase Ib study as a result of a pause by some CRO partners in response to the COVID-19 pandemic | 3/30/20 |
| Cumberland Pharmaceuticals Inc., of Nashville, Tennessee | Ifetroban Sodium | Malignant solid tumor | Phase II study paused due to COVID-19 | 3/30/20 |
| Curis Inc., of Lexington, Mass. | CA-4948 | Relapsed or refractory non-Hodgkin lymphoma | Due to COVID-19, certain sites remain open for enrollment while others have temporarily halted enrollment of new patients; company expects to report updated efficacy data from study and declare recommended phase II dose in 2020 | 5/12/20 |
| Cyclerion Therapeutics Inc., of Cambridge, Mass. | IW-6463 | Neurodegenerative disease | Study in healthy elderly participants terminated; some subjects could not complete second crossover period due to COVID-19-related site closure; study closed to allow analysis of all collected data | 6/19/20 |
| Cytokinetics Inc., of South San Francisco | CK-274 | Hypertrophic cardiomyopathy | Enrollment in the phase II Redwood-HCM study of the myosin inhibitor paused due to COVID-19 pandemic; data from first cohort may be available in second half of 2020 if cohort's enrollment is completed by midyear 2020 | 4/14/20 |
| Cytokinetics Inc., of South San Francisco, and Amgen Inc., of Thousand Oaks, Calif. | AMG-594 | Heart failure | Enrollment in a phase I trial of the cardiac troponin activator is suspended due to COVID-19 pandemic | 4/14/20 |
| Cytokinetics Inc., of South San Francisco, and Amgen Inc., of Thousand Oaks, Calif. | Omecamtiv mecarbil | Heart failure | Enrollment in Meteoric-HF phase III trial of the myosin stimulator paused due to COVID-19 pandemic; risk mitigation for enrolled participants includes remote study visits and home delivery of study drug; site startup activities continue, and enrollment of 270 planned participants may be completed by year-end 2020 if enrollment is reactivated by end of second quarter 2020 | 4/14/20 |
| Cytomx Therapeutics Inc., of South San Francisco | CX-072 | Melanoma | Terminating the Proclaim-CX-072-002 study evaluating the PD-L1 probody CX-072 in combination with Yervoy (ipilimumab), following a re-evaluation of the clinical, competitive and commercial landscapes, as well as the impact of COVID-19; the decision frees up resources for other projects | 3/31/20 |
| Cytomx Therapeutics Inc., of South San Francisco | CX-2009 | Hormone receptor positive HER2 negative breast cancer | Pausing new patient enrollment and new site activation in the Proclaim-CX-2009-001 study evaluating the CD166-targeting probody drug conjugate | 3/31/20 |
| Daiichi Sankyo Co. Ltd., of Tokyo | DS-8201a | Advanced breast cancer | Suspended due to COVID-19 | 4/20/20 |
| Denali Therapeutics Inc., of South San Francisco | DNL-151 | Parkinson’s disease | Enrollment in phase I and phase Ib studies paused due to COVID-19; analyzing data from studies; plans to select DNL-151 or DNL-201 for phase II/III development by mid-2020 | 4/3/20 |
| Denali Therapeutics Inc., of South San Francisco | DNL-310 | Hunter syndrome | Phase I study remains on track to start in the second quarter; enrollment in observational biomarker study paused due to COVID-19 | 4/3/20 |
| Denali Therapeutics Inc., of South San Francisco | DNL-343 | Healthy volunteers (eventually amyotrophic lateral sclerosis/frontotemporal degeneration) | Phase I enrollment paused due to COVID-19 | 4/3/20 |
| Dermira Inc., of Menlo Park, Calif. | Lebrikizumab | Moderate-to-severe atopic dermatitis | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/6/20 |
| Dermira Inc., of Menlo Park, Calif. | Lebrikizumab plus topical corticosteroid | Moderate-to-severe atopic dermatitis | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/6/20 |
| Desentum Oy, of Espoo, Finland | DM-101 | Birch pollen allergy | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/3/20 |
| Destiny Pharma plc, of Brighton, U.K. | XF-73 | Prevention of postsurgical infections | Phase IIIb study paused due to COVID-19 pandemic | 4/29/20 |
| Dicerna Pharmaceuticals Inc., of Lexington, Mass. | Nedosiran | Primary hyperoxaluria | Due to COVID-19, there has been a temporary suspension of further clinical trial activities at multiple sites and the company no longer expects to complete enrollment in the pivotal trial in the second quarter of 2020 | 3/27/20 |
| Diffusion Pharmaceuticals Inc., of Charlottesville, Va. | TSC (trans sodium crocetinate) | Acute stroke | Enrollment delay expected in ambulance-based PHAST-TSC trial of the Vitamin A analogue due to COVID-19 | 3/25/20 |
| Eiger Biopharmaceuticals Inc., of Palo Alto, Calif. | Lonafarnib | Hepatitis delta virus infection | Completion of D-LIVR study enrollment shifted into 2021 due to COVID-19; Farnesyl transferase inhibitor | 4/2/20 |
| Eli Lilly and Co., of Indianapolis | LY-3526318 | Pain | Study in healthy volunteers terminated due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | Abemaciclib | HR-positive, HER2-negative metastatic breast cancer | Enrolling in study testing combination with fulvestrant vs. chemotherapy on hold due to COVID-19 | 4/27/20 |
| Eli Lilly and Co., of Indianapolis | Ixekizumab | Plaque psoriasis | Suspended due to COVID-19 pandemic | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-2963016 | Type 2 diabetes | Study in India suspended due to COVID-19 | 4/28/20 |
| Eli Lilly and Co., of Indianapolis | LY-3009104 (baricitinib) | Rheumatoid arthritis | Enrollment on hold in Ra-Branch study due to COVID-19 | 4/28/20 |
| Eli Lilly and Co., of Indianapolis | LY-3009104 (baricitinib) | Active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis | Enrollment on hold due to COVID-19 | 4/28/20 |
| Eli Lilly and Co., of Indianapolis | LY-3305677 | Type 2 diabetes | Suspended due to COVID-19 pandemic | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3361237 | Systemic lupus erythematosus | Suspended due to COVID-19 pandemic | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3372689 | Alzheimer's disease | Enrollment of healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3454738 | Atopic dermatitis | Suspended enrollment due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3454738 | Chronic spontaneous urticaria | Enrollment on hold due to COVID-19 | 4/27/20 |
| Eli Lilly and Co., of Indianapolis | LY-3462817 | Psoriasis | Enrollment on hold due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3463251 | Diabetes | Enrollment of healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3471851 | Psoriasis | Enrollment on hold due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3471851 | Eczema | Enrollment on hold due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3475070 | Advanced cancer | Enrollment in study testing combination with Keytruda (pembrolizumab, Merck & Co. Inc.) on hold due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3475766 | Cardiovascular disease | Enrollment of healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3478045 | Endocrine/metabolic diseases | Enrollment of healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3499446 | Advanced solid tumors | Enrollment in phase I/II trial of patients with KRAS G12C mutation on hold due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-3502970 | Endocrine/metabolic disorders | Trial in healthy volunteers suspended due to COVID-19 | 5/1/20 |
| Eli Lilly and Co., of Indianapolis | LY-3556050 | Pain | Enrollment of healthy volunteers suspended due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | LY-900014 | Type 2 diabetes | Enrollment in study comparing drug to Humalog suspended due to COVID-19 | 6/5/20 |
| Eli Lilly and Co., of Indianapolis | LY-900014 | Type 1 diabetes | Suspended due to COVID-19 pandemic | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | Tirzepatide | Type 2 diabetes | Enrollment in contraceptive pharmacokinetics study in healthy female volunteers halted due to COVID-19 | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | Tirzepatide | Impaired liver function | Suspended due to COVID-19 pandemic | 4/22/20 |
| Eli Lilly and Co., of Indianapolis | Trulicity (dulaglutide) | Type 2 diabetes | New 36-week data from Award-11 trial showed higher doses (3 mg and 4.5 mg) were well-tolerated and led to A1C reduction up to 1.9% and weight reduction up to 10.4 pounds | 5/8/20 |
| Eli Lilly and Co., of Indianapolis | Various drugs | Various indications | Lilly said it is delaying most of its new clinical trial starts and pausing enrollment in most of its ongoing studies while continuing those for patients who are already enrolled; the move is to focus on COVID-19 R&D and easing the burden on health care facilities | 3/23/20 |
| Eloxx Pharmaceuticals Inc., of Waltham, Mass. | ELX-02 | Cystic fibrosis | Enrollment in phase II program temporarily paused due to COVID-19 pandemic; ELX-02 is a CFTR gene modulator | 3/25/20 |
| Enanta Pharmaceuticals Inc., of Watertown, Mass. | EDP-305 | Non-alcoholic steatohepatitis | In response to the COVID-19 pandemic, it has paused recruitment and dosing in its Argon-2 phase IIb NASH study | 3/27/20 |
| Enanta Pharmaceuticals Inc., of Watertown, Mass. | EDP-514 | Hepatitis B virus | In response to the COVID-19 pandemic, it has paused recruitment in part 2 of a phase Ia/Ib study in nuc-suppressed hepatitis B patients | 3/27/20 |
| Endo Pharmaceuticals plc, of Dublin | Collagenase Clostridium histolyticum (EN-3835) | Cellulite | Phase IIa study testing CCH in buttock and thigh cellulite in adult women temporarily suspended due to COVID-19 disruptions | 7/28/20 |
| Equillium Inc., of La Jolla, Calif. | EQ-001 (itolizumab) | Asthma; lupus nephritis | To protect patients, caregivers and employees, company has paused enrollment in the Equip trial for uncontrolled asthma and the Equalise trial for lupus nephritis; itolizumab is a monoclonal antibody that targets the CD6-ALCAM pathway | 3/26/20 |
| Exelixis Inc., of Alameda, Calif. | Cabozantinib | Prostate cancer | Trial testing drug followed by prostatectomy in high-risk patients suspended due to COVID-19 | 4/22/20 |
| Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland | FE-999049 + GnRH agonist | Infertility | Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic | 3/24/20 |
| Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland | Menopur | Infertility | Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic | 3/24/20 |
| Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland | Quinagolide vaginal ring | Endometriosis-related pain | Recruitment of phase II trial temporarily halted due to the COVID-19 pandemic | 3/31/20 |
| Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland | Quinagolide vaginal ring | Endometriosis | Recruitment of phase II trial temporarily halted due to the COVID-19 pandemic | 4/7/20 |
| Flexion Therapeutics Inc., of Burlington, Mass. | FX-201 | Osteoarthritis of the knee | Suspending the phase I study temporarily to ensure the safety of trial participants during the COVID-19 pandemic | 4/1/20 |
| Flexion Therapeutics Inc., of Burlington, Mass. | Zilretta | Shoulder osteoarthritis or adhesive capsulitis | Suspending the phase II trial temporarily to ensure patient safety during the COVID-19 pandemic | 4/1/20 |
| Forty Seven Inc., of Menlo Park, Calif. | FSI-174 | Hematologic cancer | Start of the phase I trial of the cKIT tyrosine kinase inhibitor in healthy volunteers id delayed due to COVID-19 | 3/20/20 |
| Fulcrum Therapeutics Inc., of Cambridge, Mass. | Losmapimod | Facioscapulohumeral muscular dystrophy | Phase IIb Redux4 trial of the p38 alpha/beta MAP kinase inhibitor is fully enrolled but trial activity suspended at many sites due to COVID-19 pandemic; top-line data for primary endpoint of change from baseline in DUX4 activity may not be available by end of third quarter of 2020, as planned | 4/2/20 |
| Galecto Inc., of Boston | GB-1211 | Nonalcoholic steatohepatitis and liver fibrosis | Phase I/II trial withdrawn due to COVID-19 pandemic and change in clinical development strategy for compound | 2/4/21 |
| Galmed Pharmaceuticals Inc., of Tel Aviv, Israel | Aramchol | Nonalcoholic steatohepatitis and fibrosis | Decided to temporarily halt screening of new patients for phase III/IV Armor study due to COVID-19, and aims to resume activity on a country by country, state by state and site by site basis as conditions improve | 5/14/20 |
| Genentech, of South San Francisco, a unit of the Roche Group | Carboplatin with or without Atezolizumab | Stage iv triple negative breast cancer | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Genentech, of South San Francisco, a unit of the Roche Group | Xolair (omalizumab) | Moderate to severe allergic asthma | Recruitment and screening visits suspended until further notice due to the COVID-19 pandemic | 4/17/20 |
| Geneuro SA, of Geneva | Temlimab | Multiple sclerosis | Postponing its planned phase II trial at the Karolinska Institute's Academic Specialist Center in Stockholm to prioritize healthcare resources behind the fight of COVID-19 and to reduce the risk for MS patients | 3/19/20 |
| Genfit SA, of Lille, France | Elafibranor | Non-alcoholic steatohepatitis and primary biliary cholangitis | Pausing all phase I trials due to COVID-19; the studies are necessary to support the NDA submission for NASH; enrollment of patients in the pharmacokinetic and pharmacodynamic trial in pediatric patients with NASH and the phase II study addressing liver fat have also been paused; has also put on hold the start of a phase II combination study and a phase III study in patients with | 3/31/20 |
| Gensight Biologics SA, of Paris | GS-030 | Retinitis pigmentosa | Recruitment of third cohort of 3 participants to receive maximal dose of the channel rhodopsin gene stimulator delayed due to COVID-19 pandemic but expected to complete in second half of 2020 | 4/14/20 |
| Geron Corp., of Menlo Park, Calif. | Imetelstat | Myelodysplastic syndrome and acute myelogenous leukemia | Due to COVID-19, company does not expect to complete enrollment in the Imerge phase III trial or to begin the proof-of-concept study in high-risk MDS and AML by the end of 2020, as originally planned | 4/2/20 |
| Geron Corp., of Menlo Park, Calif. | Imetelstat | Lower-risk myelodysplastic syndromes | Due to effects of COVID-19 pandemic on site initiations and enrollment, patient enrollment now expected to complete by end of first quarter of 2021, with top-line results expected in second half of 2022 | 5/22/20 |
| Glaxosmithkline plc, of London | Belimumab | Kidney transplant | Phase I study suspended due to COVID-19 | 3/27/20 |
| Glaxosmithkline plc, of London | Bexsero | Meningococcal disease | Study, in infants 6 weeks through 12 months of age, when administered with pneumococcal conjugate vaccine, has temporarily suspended recruitment activities due to the COVID-19 pandemic | 4/17/20 |
| Glaxosmithkline plc, of London | Clostridium difficile vaccine based on the F2 antigen | Clostridium difficile infection | Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Glaxosmithkline plc, of London | Daprodustat | Anemia | Recruitment of phase I trial temporarily suspended due to COVID-19 | 4/14/20 |
| Glaxosmithkline plc, of London | Daprodustat | Anemia in chronic kidney disease | Recruitment in study comparing effect of drug to darbepoetin alfa on endothelial function by assessing forearm blood flow temporarily paused due to COVID-19 | 5/4/20 |
| Glaxosmithkline plc, of London | Dolutegravir/lamivudine | Therapy-naive HIV-infected adolescents | Recruitment suspended due to COVID-19 pandemic | 4/17/20 |
| Glaxosmithkline plc, of London | GSK-1437173A | Herpes Zoster | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Glaxosmithkline plc, of London | GSK-1437173A | Shingles in children with kidney transplant | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Glaxosmithkline plc, of London | GSK-3036656 | Drug-sensitive pulmonary tuberculosis | Recruitment activities suspended due to COVID-19 | 4/22/20 |
| Glaxosmithkline plc, of London | GSK-3196165 (otilimab) | Rheumatoid arthritis | Study testing drug vs. placebo and sarilumab in patients with moderately to severely active disease who have inadequate response to disease-modifying therapy and/or JAK inhibitors temporarily suspended recruitment due to COVID-19 | 4/28/20 |
| Glaxosmithkline plc, of London | GSK-3196165 (otilimab) | Rheumatoid arthritis | Study testing drug vs. placebo tofacitinib in patients with moderately to severely active disease who have inadequate response to methotrexate temporarily suspended recruitment due to COVID-19 | 4/28/20 |
| Glaxosmithkline plc, of London | GSK-3858279 | Pain | Recruitment activities in study testing battery of evoked pain tests in healthy volunteers temporarily suspended due to COVID-19 | 5/25/20 |
| Glaxosmithkline plc, of London | GSK-3858279 | Osteoarthritis | Recruitment suspended due to COVID-19, though other elements of study are ongoing | 4/24/20 |
| Glaxosmithkline plc, of London | HBV (Hepatitis B Virus) viral vector vaccines and adjuvanted proteins vaccine (GSK3528869A) | Hepatitis B virus infection | Recruitment of phase I trial temporarily suspended due to COVID-19 | 4/13/20 |
| Glaxosmithkline plc, of London | Mepolizumab | Chronic obstructive pulmonary disease | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/8/20 |
| Glaxosmithkline plc, of London | RSVPreF3 vaccine | Respiratory syncytial virus infections | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Glycomimetics Inc., of Rockville, MD. | Uproleselan | Relapsed/refractory acute myeloid leukemia | Reported in first-quarter earnings that site initiation, recruitment and enrollment slowed in April due to COVID-19 | 5/1/20 |
| Gossamer Bio Inc., of San Diego | GB-002 | Pulmonary arterial hypertension | Given COVID-19-related delays in enrollment, company now anticipates reporting initial results from phase Ib trial in second half of 2020 | 5/12/20 |
| GT Biopharma Inc., of Beverly Hills, Calif. | GTB-3550 | CD33+ malignancies | Restarted enrollment in phase I/II study after a 30-day pause due to the COVID-19 pandemic | 1/12/21 |
| Helix Biopharma Corp., of Richmond Hill, Ontario | L-DOS47 | Pancreatic cancer | Phase Ib/II study (LDOS006) testing combination with doxorubicin continues to enroll and has dosed 2 patients; however, given the COVID-19 pandemic, company expects patient enrollment will be impacted; immuno-conjugate drug | 4/2/20 |
| Hookipa Pharma Inc., of New York and Vienna | HB-101 | Cytomegalovirus | Due to COVID-19 pandemic, nearly all ongoing trial sites have suspended patient enrollment; it remains unclear when kidney organ transplants will resume at any of the sites | 5/14/20 |
| Ico Therapeutics Inc., of Vancouver, British Columbia | ICO-019 (amphotericin B, oral) | Infection | Start of phase II trial of the macrolide antibiotic delayed due to COVID-19 pandemic | 4/15/20 |
| Imbrium Therapeutics LP, subsidiary of Purdue Pharma LP, of Stamford, Conn., and Spinethera Inc., of Plymouth, Minn. | V-117957 | Insomnia associated with alcohol cessation | Recruitment suspended due to COVID-19 | 4/20/20 |
| Immunomedics Inc., of Morris Plains, N.J. | Sacituzumab Govitecan | Metastatic solid tumors | Phase II study temporarily suspended due to COVID-19 | 3/25/20 |
| Immunomedics Inc., of Morris Plains, N.J. | Sacituzumab Govitecan | Metastatic breast cancer | Phase III study temporarily suspended due to COVID-19 | 3/25/20 |
| Immunomedics Inc., of Morris Plains, N.J. | Sacituzumab Govitecan | Metastatic urothelial cancer | Phase II study temporarily suspended due to COVID-19 | 3/25/20 |
| Incyte Inc., of Wilmington, Del. | Epacadostat | Locally advanced rectal cancer | Trial adding epacadostat to preoperative chemoradiation suspended due to COVID-19 | 4/22/20 |
| Incyte Inc., of Wilmington, Del. | Itacitinib | Soft tissue sarcomas | Phase I study temporarily suspended due to COVID-19 | 3/31/20 |
| Indalo Therapeutics Inc., of Cambridge, Mass. | IDL-2965 | Idiopathic pulmonary fibrosis | Study in healthy participants and IPF patients terminated due to development challenges associated with COVID-19 and emerging nonclinical data | 8/4/20 |
| Infinity Pharmaceuticls Inc., of Cambridge, Mass. | IPI-549 | Cancer | Working with clinical trial investigators and sites to continue patient treatment, but new enrollment is being assessed for each individual patients and the company expects some delays due to COVID-19; several studies are underway for the oral immuno-oncology candidate that selectively inhibits P13K-gamma | 4/7/20 |
| Inflarx NV, of Jena, Germany | IFX-1 | Various inflammatory indications | While current clinical trial sites remain active, it is possible that sites have paused or will pause screening of new patients, and there may be other delays or consequences as the pandemic evolves | 3/31/20 |
| Intra-Cellular Therapies Inc., of New York | ITI-007 (lumateperone tosylate) | Schizophrenia | Suspended due to COVID-19 | 4/20/20 |
| Inventiva SAS, of Daix, France | Lanifibranor | Nonalcoholic fatty liver disease | Recruitment and screening of new patients in the phase II trial of lanifibranor, which targets PPAR, suspended due to COVID-19; patients already included to continue receiving treatment as per protocol | 4/7/20 |
| Ipsen SA, of Paris | Botulinum toxin type A | Vulvodynia | Phase II study temporarily suspended due to COVID-19 at least until 25 April 2020 | 3/31/20 |
| Ipsen SA, of Paris, and Bristol Myers Squibb Co., of New York | Nal-irinotecan and nivolumab | Advanced biliary tract cancer | Enrollment in phase Ib/II trial testing combination in second-line therapy temporarily paused due to COVID-19 | 5/1/20 |
| Ironwood Pharmaceuticals Inc., of Boston | IW-3718 | Refractory gastroesophageal reflux disease | COVID-19 is impacting enrollment of new patients in the phase III trial due primarily to certain sites suspending enrollment and lower patient participation; nearly 70% have been enrolled to date; top-line data is no longer expected for the second half of 2020 | 3/26/20 |
| Ironwood Pharmaceuticals Inc., of Boston | IW-3718 | Refractory gastroesophageal reflux disease | COVID-19 pandemic impacting enrollment in 2 trials, with most clinical sites no longer screening new patients; top-line data no longer expected in second half of 2020 | 5/6/20 |
| Iveric Bio Inc., of New York | Zimura (avancipatad pegol) | Geographic atrophy secondary to dry age-related macular degeneration | Delaying the initiation of enrollment of patients in the second pivotal clinical trial, ISEE2008, for the novel complement C5 inhibitor; it was on track to begin in March 2020 | 3/18/20 |
| Janssen Pharmaceutica NV, a unit of New Brunswick, N.J.-based Johnson & Johnson | Apalutamide (ARN-509) | Prostate cancer patients after prostatectomy | Recruitment in trial comparing apalutamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) vs. concomitant prostate-bed SRT and ADT has been temporary suspended since March 20 due to COVID-19 pandemic | 4/24/20 |
| Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson | Guselkumab | Hidradenitis suppurativa | Study withdrawn due to COVID-19 | 6/5/20 |
| Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson | JNJ-54175446 | Major depressive disorder | Suspended due to COVID-19 | 5/18/20 |
| Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson, and Yuhan Corp., of Seoul, Korea | YH-25448 | EGFR-positive advanced non-small-cell lung cancer | Recruitment in phase I/II trial temporarily on hold due to COVID-19 | 4/28/20 |
| Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson | Loperamide | Antidiarrheal | Study testing effects on electrocardiogram intervals in healthy adults put on hold due to COVID-19 | 6/22/20 |
| Janssen Research & Development LLC, of Raritan, N.J, a unit of Johnson & Johnson | Macitentan and tadalafil | Pulmonary arterial hypertension | Study in healthy adults suspended due to COVID-19 | 6/2/20 |
| Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson | JNJ-61393215 | Depression | Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic | 4/3/20 |
| Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson | JNJ-67953964 | Healthy subjects | Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic | 4/3/20 |
| Juno Therapeutics Inc., of Seattle | Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 | Multiple myeloma | Phase I study temporarily suspended due to COVID-19 | 3/31/20 |
| Juno Therapeutics Inc., of Seattle | BCMA-specific CAR-expressing T Lymphocytes | Recurrent plasma cell myeloma | Phase I study temporarily suspended due to COVID-19 | 3/31/20 |
| Kadmon Holdings Inc., of New York | KD-025 | Systemic sclerosis | Enrollment delayed due to COVID-19 | 5/7/20 |
| Kalvista Pharmaceuticals Inc., of Cambridge, Mass. | KVD-900 | Hereditary angioedema | Data from phase II study of the plasma kallikrein inhibitor delayed due to COVID-19; expects data in second half of 2020 if participants are able to resume their activity during the second quarter of 2020 | 4/7/20 |
| Karyopharm Therapeutics Inc., of Newton, Mass. and Abbvie Inc., of North Chicago | Venetoclax and Selinexor | Diffuse large B-cell lymphoma and acute myeloid leukemia | Recruitment of phase I trial temporarily suspended due to COVID-19 | 4/14/20 |
| Kezar Life Sciences Inc., of South San Francisco | KZR-616 | Lupus nephritis | Clinical development and data release of the immunoproteasome inhibitor expected to be delayed due to COVID-19, but the open-label portion of the Mission study continues to generate data; next data update expected by the end of the second quarter of 2020 | 4/9/20 |
| Kezar Life Sciences Inc., of South San Francisco | KZR-616 | Active autoimmune hemolytic anemia or immune thrombocytopenia | Marina study withdrawn due to COVID-19-related activity slowdown, high screen fail rate and lack of enrollment | 8/5/20 |
| Leo Pharma A/S, of Ballerup, Denmark | Delgocitinib cream | Discoid lupus erythematosus | Trial put on hold due to COVID-19 | 5/4/20 |
| Leo Pharma A/S, of Ballerup, Denmark | LEO-138559 | Atopic dermatitis | Trial in healthy subjects put on hold due to COVID-19 | 4/27/20 |
| Levo Therapeutics Inc., of Chicago | Intranasal carbetocin (LV-101) | Prader-Willi syndrome | Enrollment in Care-PWS trial paused due to COVID-19 | 4/20/20 |
| Lexicon Pharmaceuticals Inc., of The Woodlands, Texas | Zynquista (sotagliflozin) | Heart failure and chronic kidney disease | Closing out early the two long-term outcomes studies, Scored and Soloist, because a near-term partnership sufficient to fund the studies to completion is now unlikely due to uncertainties related to the COVID-19 pandemic | 3/19/20 |
| Magenta Therapeutics Inc., of Cambridge, Mass. | MGTA-145 | Bone marrow transplantation | Initiation of multiple phase II trials of the CXCR2 chemokine agonist may be staggered over remainder of 2020 due to COVID-19 pandemic but initial phase II data may be available by year-end 2020, as planned | 4/16/20 |
| Magenta Therapeutics Inc., of Cambridge, Mass. | MGTA-456 (spanlecortemlocel) | Hematopoietic stem cell transplantation | Enrollment timelines for the phase II trial of the AHR gene inhibitor in inherited metabolic disorders shifted into 2021 due to COVID 19 pandemic; 16 of 18 participants enrolled in separate blood cancer trial, expected to complete enrollment in 2020 | 4/16/20 |
| Mallinckrodt plc, of Staines-upon-Thames, U.K. | Acthar | Keratitis | Phase IV study temporarily suspended due to COVID-19 | 4/2/20 |
| Mallinckrodt plc, of Staines-upon-Thames, U.K. | Acthar Gel | Uveitis | Phase IV study temporarily suspended due to COVID-19 | 4/1/20 |
| Mallinckrodt plc, of Staines-upon-Thames, U.K. | Acthar Gel (repository corticotropin injection) | Severe keratitis | Study testing impact on everyday life of patients temporarily suspended due to COVID-19 | 4/30/20 |
| Marker Therapeutics Inc., of Houston | MultiTAA-specific T-cell therapy | Acute myeloid leukemia | Due to COVID-19, initiation of trial expected to be delayed; Marker paused opening enrollment of first 3 patients, as the manufacturing facility it utilizes to supply study drug remains closed during the pandemic | 5/11/20 |
| Matinas Biopharma Holdings Inc., of Bedminster, N.J. | Amphotericin | Cryptococcal meningtitis | Enrollment of new patients in Enact (encochleated oral amphotericin for crytococcal meningitis) has been paused; two patients enrolled and dosed were moved to standard of care | 3/31/20 |
| Matinas Biopharma Holdings Inc., of Bedminster, N.J. | MAT-9001 | Hypertriglyceridemia | Paused enrollment in the Enhance-IT trial, a head-to-head with Vascepa, due to COVID-19; trial just started March 5 | 3/31/20 |
| Medexus Pharmaceuticals Inc., of Chicago, Toronto and Montreal | Ixinity | Hemophilia B | COVID-19 is resulting in meaningful delays for its pediatric trial of the intravenous recombinant factor IX therapeutic | 3/23/20 |
| Medical Developments International Ltd., of Scoresby, Australia | Penthrox | Acute pain | Phase II study suspended due to substantial study updates and COVID-19 | 3/25/20 |
| Mediwound Ltd., of Yavne, Israel | Escharex | Venous leg ulcers | Enrollment suspended in phase II trial of the topical enzyme proteolytic therapy due to COVID-19 outbreak | 3/30/20 |
| Mediwound Ltd., of Yavne, Israel | Escharex (bromelain gel) | Venous leg ulcers | Size of adaptive design study reduced to enrollment target of 120 participants from 174 due to COVID-19-related enrollment delays and potential disruptions; interim assessment expected in mid-2021 with full enrollment expected by year-end 2021 | 1/11/21 |
| Merck & Co. Inc., of Kenilworth, N.J. | Aldesleukin and Pembrolizumab | Advanced or metastatic kidney cancer | Phase I study temporarily suspended due to COVID-19 | 3/31/20 |
| Merck KGaA, of Darmstadt, Germany | M-5717 | Healthy subjects | Phase I study temporarily suspended due to COVID-19 | 3/30/20 |
| Merck, Sharp & Dohme Corp., part of Kenilworth, N.J.-based Merck & Co. Inc. | MK-8228 (letermovir) | Prevention of human cytomegalovirus infection and disease | Trial testing drug in adult Japanese kidney transplant recipients suspended due to COVID-19 | 5/6/20 |
| Merck, Sharp & Dohme Corp., part of Merck & Co. Inc., of Kenilworth, N. J. | Bezlotoxumab | Clostridium difficile infection | Study testing secondary prophylaxis in high-risk hospitalized patients exposed to antibiotics temporarily paused due to COVID-19 | 5/15/20 |
| Mesoblast Ltd., of Melbourne, Australia | Remestemcel-L | COVID-19 | Started enrolling in phase II/III placebo-controlled study to measure whether remestemcel-L provides survival benefit in moderate/severe acute respiratory distress syndrome due to COVID-19 | 4/30/20 |
| Millendo Therapeutics Inc., of Ann Arbor, Mich. | Nevanimibe | Classic congenital adrenal hyperplasia | Due to COVID-19, new patients are not being actively enrolled in phase IIb study at this time; company expects to conduct interim review of current dataset for enrolled patients by the third quarter of 2020 | 5/8/20 |
| Moderna Inc., of Cambridge, Mass. | mRNA-1653 | Human metapneumovirus and parainfluenza type 3 | Pausing new enrollment of its age de-escalation trial for its pediatric respiratory vaccine due to COVID-19 | 3/30/20 |
| Moderna Inc., of Cambridge, Mass. | mRNA-3704 | Methylmalonic acidemia | Pausing new enrollment of its phase I rare disease trials due to disruption from COVID-19 | 3/30/20 |
| Moderna Inc., of Cambridge, Mass. | mRNA-3927 | Propionic acidemia | Pausing new enrollment of its phase I rare disease trials due to disruption from COVID-19 | 3/30/20 |
| Momenta Pharmaceuticals Inc., of Cambridge, Mass. | M-281 | Warm autoimmune hemolytic anemia | Recruitment paused due to COVID-19 pandemic | 4/15/20 |
| Momenta Pharmaceuticals Inc., of Cambridge, Mass. | M-281 | Generalized myasthenia gravis | Recruitment paused due to COVID-19 pandemic | 4/15/20 |
| Momenta Pharmaceuticals Inc., of Cambridge, Mass. | M-254 (hypersialylated immunoglobulin) | Idiopathic thrombocytopenic purpura | Most sites suspended enrollment in ongoing phase I/II trial due to COVID-19 pandemic; interim data for part B may not report as planned in second quarter of 2020, which would delay initiation of parts C and D; Dendritic ICAM-3 grabbing nonintegrin 1 modulator | 4/2/20 |
| Momenta Pharmaceuticals Inc., of Cambridge, Mass. | M-254 (hypersialylated immunoglobulin) | Chronic inflammatory demyelinating polyneuropathy | Trial now expected to begin in 2021 due to COVID-19-related delays; Dendritic ICAM-3 grabbing nonintegrin 1 modulator | 4/2/20 |
| Momenta Pharmaceuticals Inc., of Cambridge, Mass. | Nipocalimab (M-281) | Hemolytic disease of fetus and newborn; warm autoimmune hemolytic anemia | Although not officially paused, Unity study in HDFN expected to enroll at slower pace due to impact of COVID-19 pandemic; global site activation continues in adaptive phase II/III Energy study in wAIHA but enrollment temporarily suspended; IgG receptor FcRn large subunit p51 antagonist | 4/2/20 |
| Morphosys AG, of Martinsried, Germany | MOR-202 | Anti-PLA2R+ membranous nephropathy | Recruitment paused in phase I/II study due to COVID-19 | 4/28/20 |
| Myokardia Inc., of Brisbane, Calif. | Danicamtiv | Genetic dilated cardiomyopathy | COVID-19 is delaying the start of the phase II study | 3/26/20 |
| Myokardia Inc., of Brisbane, Calif. | Mavacamten | Heart conditions | COVID-19 is delaying the start of the Valor-HCM phase III study for its use as an alternative to septal reduction therapy procedures and the phase II study in subgroups of patients with heart failure with preserved ejection fraction | 3/26/20 |
| Neoimmunetech Inc., of Cambridge, Mass. | rhIL-7-hyFc | Glioma | Suspended trial in patients with newly diagnosed non-lymphopenic gliomas following radiation and temozolomide due to COVID-19 | 4/22/20 |
| Neurocrine Biosciences Inc., of San Diego | Crinecerfont | Congenital adrenal hyperplasia | Phase II enrollment paused due to COVID-19 | 4/3/20 |
| Neurocrine Biosciences Inc., of San Diego | Ingrezza (valbenazine ) | Chorea in Huntington disease | Phase III enrollment paused due to COVID-19 | 4/3/20 |
| Neurocrine Biosciences Inc., of San Diego, and Voyager Therapeutics Inc., of Cambridge, Mass. | NBIb-1817 | Parkinson's disease | Phase II enrollment in the Restore-1 study paused due to COVID-19 | 4/3/20 |
| Newron Pharmaceuticals SpA, of Milan, Italy | Evenamide | Schizophrenia | Expects a delay in the start of its planned studies, due to the prioritiation of hospital staff to care for COVID-19 patients over research studies | 3/31/20 |
| Nextcure Inc., of Beltsville, Md. | NC-318 | Advanced solid tumors | Company continuing to support those enrolled in phase II portion of phase I/II monotherapy trial of the sialic acid-binding lg-like lectin 15 inhibitor and working with sites to enroll additional participants as appropriate in light of COVID-19 pandemic; initial biomarker data from phase I portion expected in midyear 2020 but top-line data from phase II portion expected to be delayed | 4/13/20 |
| Nextcure Inc., of Beltsville, Md. | NC-318 | Advanced solid tumors; non-small-cell lung cancer | Initiation of combination trial of the sialic acid-binding Ig-like lectin 15 inhibitor with standard-of-care chemotherapies delayed due to COVID-19 pandemic | 4/13/20 |
| Nextcure Inc., of Beltsville, Md. | NC-410 | Undisclosed cancer | Initiation of phase I portion of phase I/II trial of the leukocyte associated Ig like receptor 1 antagonist, originally expected to begin in March, delayed due to COVID-19 pandemic | 4/13/20 |
| Northwest Biotherapeutics Inc., of Bethesda, Md. | Dcvax-L | Glioblastoma | COVID-19 has delayed final data collection; expected to be complete in mid-June 2020 or shortly thereafter | 6/2/20 |
| Novartis AG, of Basel, Switzerland | CFZ-533 | Type 1 diabetes | Treatment and recruitment paused due to COVID-19 | 4/15/20 |
| Novartis AG, of Basel, Switzerland | BAF-312 (siponimod) | Intracerebral hemorrhage | Recruitment temporarily paused due to COVID-19 | 5/4/20 |
| Novartis AG, of Basel, Switzerland | Brolucizumab | Macular edema secondary to retinal vein occlusion | Trial temporarily paused due to COVID-19 and safety measure | 6/1/20 |
| Novartis AG, of Basel, Switzerland | Brolucizumab | Diabetic macular edema | Study testing drug vs. aflibercept in patients with visual impairment due to DME canceled due to COVID-19 | 3/4/21 |
| Novartis AG, of Basel, Switzerland | Canakinumab | Early stage non-small-cell lung cancer | Recruitment temporarily paused due to COVID-19 in study testing canakinumab or Keytruda (pembrolizumab, Merck & Co. Inc.) as monotherapy or combination therapy in neoadjuvant treatment | 4/28/20 |
| Novartis AG, of Basel, Switzerland | CFZ-533 | Sjogren’s syndrome | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/13/20 |
| Novartis AG, of Basel, Switzerland | Crizanlizumab | Sickle cell disease | Recruitment temporarily paused due to COVID-19 in trial enrolling adolescent and adult patients | 4/28/20 |
| Novartis AG, of Basel, Switzerland | Crizanlizumab | Sickle cell disease | Recruitment in study enrolling pediatric patients temporarily paused due to COVID-19 | 5/1/20 |
| Novartis AG, of Basel, Switzerland | Entresto (sacubitril/valsartan) | Heart failure with preserved ejection fraction | Recruitment temporarily paused due to COVID-1 | 4/17/20 |
| Novartis AG, of Basel, Switzerland | Sacubitril/Valsartan | Chronic Chagas' cardiomyopathy | Recruitment of phase IV trial temporarily paused due to the COVID-19 pandemic | 4/13/20 |
| Novartis AG, of Basel, Switzerland | Secukinumab | Necrobiosis lipoidica diabeticorum | Enrollment and other trial activities paused due to COVID-19 pandemic | 4/24/20 |
| Novartis AG, of Basel, Switzerland | Secukinumab | Plaque psoriasis and coexisting nonalcoholic fatty liver disease | Study suspended due to COVID-19 | 4/28/20 |
| Novartis AG, of Basel, Switzerland | Secukinumab | Hidradenitis suppurativa | Suspended due to COVID-19 | 4/28/20 |
| Novartis AG, of Basel, Switzerland | Spartalizumab | Unresectable or metastatic melanoma | Recruitment paused due to COVID-19 pandemic | 4/24/20 |
| Novartis AG, of Basel, Switzerland | Tropifexor/licogliflozin | Nonalcoholic steatohepatitis | Recruitment suspended due to COVID-19 pandemic | 4/24/20 |
| Novo Nordisk A/S, of Bagsvaerd, Denmark | Degludec | Type 2 diabetes | Recruitment in study comparing drug and glargine U100 for management of hospitalized and discharged patients suspended due to COVID-19 | 5/4/20 |
| Novo Nordisk A/S, of Bagsvaerd, Denmark | Liraglutide | Type 2 diabetes | Recruitment suspended in hospital discharge trial due to COVID-19 | 5/4/20 |
| Novocure Ltd., of St. Helier, Jersey | Optune | Newly diagnosed unresectable glioblastoma | Recruitment temporarily suspended due to COVID-19 pandemic | 4/24/20 |
| Obi Pharma Inc., of Taipei, Taiwan | Adagloxad simolenin | Triple-negative breast cancer | Pausing the Gloria study of the antibody-drug conjugate targeting Clobo H for 3 months due to COVID-19 | 4/8/20 |
| Obseva SA, of Geneva | Lizagolix | Endometriosis | Screening and randomization in ongoing Edelweiss 2 and 3 trials is placed on voluntary hold due to COVID-19; Linzagolix is a GNRH receptor antagonist | 3/23/20 |
| Ocular Therapeutix Inc., of Bedford, Mass. | Dextenza | Cataract | Recruitment of phase IV trial was temporarily suspended due to the COVID-19 pandemic | 4/3/20 |
| Opiant Pharmaceuticals Inc., of Santa Monica, Calif. | OPNT-002 (naltrexone hydrochloride, intranasal) | Alcohol use disorder | Paused initiation of recruitment due to COVID-19 pandemic | 5/12/20 |
| Oramed Pharmaceuticals Inc., of New York | Oral leptin edrug candidate | Type 1 diabetes | Delaying its exploratory clinical study due to the COVID-19 outbreak | 4/1/20 |
| Orchard Therapeutics plc, of London | OTL-101 (simoladagene autotemcel) | Severe combined immunodeficiency | COVID-19-related clinical and manufacturing impacts expected to delay initiation of rolling BLA to FDA, previously planned for first half of 2020 | 4/1/20 |
| Orchard Therapeutics plc, of London | OTL-103 | Wiskott-Aldrich syndrome | Enrollment timelines in ongoing trial expected to shift by at least 3 months due to COVID-19 pandemic | 4/1/20 |
| Orchard Therapeutics plc, of London | OTL-200 | Metachromatic leukodystrophy | Despite continuing engagement with EMA on submitted MAA under accelerated assessment, decision likely to be postponed due to COVID-19 pandemic; potential launch in Europe now expected in first half of 2021; BLA submission to FDA also postponed to first half of 2021 | 4/1/20 |
| Orchard Therapeutics plc, of London | OTL-201 | Mucopolysaccharidosis type IIIA (Sanfilippo syndrome) | Enrollment timelines in ongoing phase I/II program expected to shift by at least 3 months due to COVID-19 pandemic | 4/1/20 |
| Orphomed Inc., of San Francisco | ORP-101 | Irritable bowel syndrome with diarrhea | Paused new patient recruitment for its phase II trial in response to the COVID-19 pandemic | 3/31/20 |
| Oryzon Genomics SA, of Madrid, Spain | Vafidemstat (ORY-2001) | Agitation-aggression in borderline personality disorder | Decided to postpone activation of phase IIb trial for a few months due to COVID-19 lockdown | 4/17/20 |
| OSE Immunotherapeutics, of Nantes, France | Tedopi | Pancreatic cancer | Patient screening and accrual in the Tedopam study are expected to be impacted by the COVID-19 situation in the coming months | 3/26/20 |
| OSE Immunotherapeutics, of Nantes, France | Tedopi | Non-small-cell lung cancer | Hit the primary endpoint in the first part of a phase III trial, but had to terminate without completing the crucial second part, due to the vulnerability of patients with metastatic NSCLC during the COVID-19 pandemic | 4/1/20 |
| OSE Immunotherapeutics, of Nantes, France, and Boehringer Ingelheim | BI-765063 (formerly OSE-172) | Solid tumors | Phase I trial is expected to be impacted by COVID-19 with regard to the screening and accrual of new patients in the second quarter of 2020 | 3/26/20 |
| OSE Immunotherapeutics, of Nantes, France, and Servier | OSE-127 | Sjögren’s syndrome | Initiation of both phase II trials in 2020 is subject to the evolution of the COVID-19 situation | 3/26/20 |
| Otonomy Inc., of San Diego | OTO-413 | Speech-in-noise-hearing difficulty | Study, which has completed several dose cohorts of the brain-derived neurotrophic factor, is paused due to COVID-19 | 4/9/20 |
| Outlook Therapeutics Inc., of Cranbury, N.J. | ONS-5010/Lytenava (bevacizumab-vikg) | Wet age-related macular degeneration | Final enrollment in Norse 2 phase III registration trial of the VEGF ligand inhibitor expected to be delayed by 1 to 3 months due to COVID-19 pandemic | 4/14/20 |
| Oxurion NV, of Leuven, Belgium | THR-687 | Diabetic macular edema | Delayed start of planned study to test multiple doses of drug due to COVID-19 pandemic; trial to start as soon as conditions allow | 5/7/20 |
| Oyster Point Pharma Inc., of Princeton, N.J. | OC-01 | Dry eye disease | Completed enrollment of 758 patients in the Onset-2 phase III study; data expected by the end of the second quarter of 2020; day 28 data impacted by COVID-19, which is predicted to reduce power for primary endpoint to 99% | 3/30/20 |
| Palatin Technologies Inc., of Cranbury, N.J. | PL-8177 | Ulcerative colitis | Delay of 2 quarters due to COVID-19; study now targeted to start in first half of 2021, with data readout in first half of 2022 | 4/30/20 |
| Palatin Technologies Inc., of Cranbury, N.J. | PL-9643 | Dry eye disease | Enrollment of additional cohorts delayed due to COVID-19; anticipates restarting enrollment in June 2020, and data readout remains on track for fourth quarter of 2020 | 4/30/20 |
| Paratek Pharmaceuticals Inc., of Boston | Various drugs | Various indications | Pausing its ongoing clinical studies due to COVID-19 | 4/2/20 |
| PCI Biotech AS, of Oslo, Norway | Fimachem | Bile duct cancer | COVID-19 has affected the opening of new trial sites and new patient enrollment in the Release study | 3/25/20 |
| PDS Biotechnology Corp., of Princeton, N.J. | PDS-0101 | Head and neck cancer | Initiation of Versatile-0022 phase II trial of the cationic lipid nanoparticle formulated vaccine in individuals with advanced/metastatic disease delayed due to COVID-19 pandemic | 4/16/20 |
| Pfizer Inc., of New York | Glasdegib | Acute myeloid leukemia | Temporary recruitment hold for trial in older patients with poor-risk AML due to COVID-19 | 7/2/20 |
| Pfizer Inc., of New York | Various drugs | Various indications | Due to COVID-19, pausing for three weeks the recruitment portion of new and ongoing clinical studies, including those for oncology and for its Duchenne muscular dystrophy gene therapy program | 3/26/20 |
| Pharming Technologies B.V. of Leiden, the Netherlands | Ruconest | Kidney failure | Phase I study temporarily suspended due to COVID-19 | 3/27/20 |
| Phasebio Pharmaceuticals Inc., of Malvern, Pa. | PB-1046 | Pulmonary arterial hypertension | Pausing enrollment in the phase II study of the sustained-release vasoactive intestinal peptide analogue due to COVID-19 | 3/30/20 |
| Phathom Pharmaceuticals Inc., of Florham Park, N.J. | Vonoprazan | Erosive esophagitis and H. pylori infection | Pausing new patient randomization in its Phalcon-EE and Phalcon-HP clinical trials due to global efforts to combat COVID-19 | 3/19/20 |
| Precigen Inc., of Germantown, Md. | PRGN-3005 | Advanced recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer | Phase I study suspended due to COVID-19 | 3/30/20 |
| Prilenia Therapeutics BV, of Naarden, the Netherlands | Pridopidine | Levodopa-induced dyskinesia in Parkinson’s disease | Study terminated due to COVID-19 | 11/9/20 |
| Progenics Pharmaceuticals Inc., of New York | 1095 | Metastatic castration-resistant prostate cancer | Due to COVID-19, decided to place enrollment of new patients on hold in Arrow study testing combination with enzalutamide in chemotherapy-naïve patients | 5/7/20 |
| Prometic Biosciences Inc., of Laval, Quebec | PBI-4050 | Alstrom syndrome | Phase II/III study terminated early due to redeployment of study site staff during COVID-19 pandemic | 10/30/20 |
| Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass. | QR-1123 | Retinitis pigmentosa | Enrollment paused due to COVID-19 pandemic | 3/31/20 |
| Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass. | QR-421a | Usher syndrome | Enrollment paused in the phase I/II trial due to COVID-19 pandemic | 3/31/20 |
| Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass. | QR-504a | Corneal dystrophy | Trial start delayed due to COVID-19 pandemic | 3/31/20 |
| Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass. | Sepofarsen | Leber congenital amaurosis 10 | Delays are expected in all ongoing and scheduled trials, including the pivotal trial of sepofarsen, due to COVID-19 | 3/31/20 |
| Provention Bio Inc., of Oldwick, N.J. | PRV-031 (teplizumab) | Type 1 diabetes | Pausing the randomization of patients into its global phase III Protech study; those undergoing study therapy will be allowed to complete their course, as recommended by the study's Data Safety Monitoring Board, which was expanded to include infectious diseases expertise; company remains on track to complete a rolling BLA to the FDA in the fourth quarter of 2020 | 3/16/20 |
| Pulmatrix Inc., of Lexington, Mass. | PUR-1900 | Allergic bronchopulmonary Aspergillosis | Study suspended due to COVID-19 pandemic | 6/9/20 |
| Pulmocide Ltd., of London | PC-945 | Aspergillus fumigatus lung infection in lung transplant | Study terminated early due to COVID-19 | 6/12/20 |
| Pulmocide Ltd., of London | PC-945 | Aspergillus fumigatus lung infection in cystic fibrosis | Study terminated early due to COVID-19 | 6/12/20 |
| Pulmocide Ltd., of London | PC-945 | Aspergillus or Candida lung infections in asthma or chronic respiratory disease | Study terminated early due to COVID-19 | 6/12/20 |
| Quantum Genomics SAS, of Paris | QGC-001 | End-stage renal failure | All patients with renal failure enrolled and treated in the phase I trial of the aminopeptidase A inhibitor; half of healthy volunteers completed the trial but enrollment temporarily halted due to COVID-19; in order to limit impact to trial, company will conduct interim analysis | 4/7/20 |
| Reata Pharmaceuticals Inc., of Plano, Texas | Bardoxolone methyl | Connective tissue disease-associated pulmonary arterial hypertension | Due to the risk of severe, adverse outcomes associated with COVID-19 among patients with respiratory and autoimmune diseases, company has stopped the phase III Catalyst study; company is also closing Ranger, the open-label extension study | 3/31/20 |
| Reata Pharmaceuticals Inc., of Plano, Texas | Bardoxolone methyl | Autosomal dominant polycystic kidney disease | Paused enrollment of new patients in the phase III Falcon trial, due to COVID-19 | 3/31/20 |
| Redhill Biopharma Ltd., of Tel Aviv, Israel | RHB-204 | Pulmonary nontuberculous mycobacteria infections | Initiation of the pivotal phase III trial is delayed by one quarter to the third quarter of this year due to the COVID-19 virus outbreak | 3/25/20 |
| Regenerx Biopharmaceuticals Inc., of Rockville, Md. | RGN-259 | Dry eye syndrome | Completion of the Arise-3 study expected to be delayed by approximately 2 months due to COVID-19 | 6/2/20 |
| Reneuron Group plc, of London | ReN-001 | Stroke disability | COVID-19 pandemic is affecting most studies, including in the U.S., where it is running trials with its stem cell therapy candidates; company expects delays in additional recruitment | 4/7/20 |
| Reneuron Group plc, of London | ReN-003 | Retinitis pigmentosa | COVID-19 pandemic is affecting most studies, including in the U.S., where it is running trials with its stem cell therapy candidates; company expects delays in additional recruitment | 4/7/20 |
| Respivant Sciences Inc., of San Diego | RVT-1601 | Persistent cough in idiopathic pulmonary fibrosis | Terminated due to COVID-19 | 6/11/20 |
| Restorbio Inc., of Boston | RTB-101 | Parkinson’s disease | Postponing enrollment of fifth cohort in the phase I due to COVID-19 | 4/3/20 |
| Retinset SL, of Barcelona, Spain | Bosentan | Type 2 diabetes | Suspended due to COVID-19 restrictions in Spain | 5/22/20 |
| Revance Therapeutics Inc., of Newark, Calif. | DaxibotulinumtoxinA (DAXI) | Adult upper limb spasticity | Paused its phase II Juniper trial due to limitations placed upon the study by COVID-19 | 3/27/20 |
| Revance Therapeutics Inc., of Newark, Calif. | RT-002 | Upper limb spasticity | Disclosed pause in enrollment in Juniper trial in adults due to COVID-19 | 5/7/20 |
| Rezolute Inc., of Redwood City, Calif. | RZ-358 | Congenital hyperinsulinism | Enrollment in recently initiated phase IIb study paused due to COVID-19; company no longer expects to report mid-study data by fourth quarter 2020 | 5/15/20 |
| Rheacell GmbH & Co. KG, of Heidelberg, Germany | Allo-APZ2-PAOD | Peripheral arterial occlusive disease | Phase I/II study terminated due to very slow enrollment amid COVID-19 pandemic | 6/29/20 |
| Rhovac AB, of Stockholm | RV-001 | Prostate cancer | Phase IIb Bravac study delayed as COVID-19 vaccinations are rolled out to study population | 3/8/21 |
| Rhovac AB, of Stockholm | RV-001 | Prostate cancer | Recruitment being delayed due to COVID-19; company expects existing financing will cover the expected delay; Antigen-based cancer therapy | 4/2/20 |
| Roche Holding AG, of Basel, Switzerland | Atezolizumab | Muscle invasive bladder cancer | Study in patients with MIBC not eligible for radical cystectomy suspended due to COVID-19 | 4/22/20 |
| Roche Holding AG, of Basel, Switzerland | Entrectinib | Cancer | Due to COVID-19, recruitment on hold to assess effect of impaired hepatic function on pharmacokinetics in volunteers with different levels of hepatic function | 5/14/20 |
| Roche Holding AG, of Basel, Switzerland | Port Delivery System with Ranibizumab | Diabetic macular edema | Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic | 4/7/20 |
| Roche Holding AG, of Basel, Switzerland | Ranibizumab | Diabetic macular edema | Enrollment in study comparing port delivery system to intravitreal administration temporarily paused due to COVID-19 | 5/19/20 |
| Sanofi Pasteur, a unit of Sanofi SA, of Paris | VRVg-2 | Rabies | Suspended due to COVID-19 | 4/30/20 |
| Sanofi SA, of Paris | Jevtana (cabazitaxel) | High-risk localized prostate cancer | Trial testing cabazitaxel and pelvic radiotherapy has been temporary suspended since March 20 due to COVID-19 pandemic | 4/24/20 |
| Sanofi SA, of Paris | Quadrivalent meningococcal conjugate vaccine | Healthy subjects | Recruitment of phase III trial was suspended due to the COVID-19 pandemic | 4/3/20 |
| Sanofi SA, of Paris | Quadrivalent meningococcal conjugate vaccine | Meningococcal Infections | Recruitment of phase III trial was suspended due to the COVID-19 pandemic | 4/3/20 |
| Sanofi SA, of Paris | VYF-01 | Yellow fever virus infection | Phase I/II study suspended due to COVID-19 | 4/15/20 |
| Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y. | Kevzara (sarilumab) | Polymyalgia rheumatica | Recruitment temporarily halted as a precautionary measure due to the COVID-19 pandemic | 4/17/20 |
| Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y. | Kevzara (sarilumab) | Giant cell arteritis | Study suspended due to COVID-19 | 4/17/20 |
| Savara Inc., of Austin, Texas | Molgradex | Nontuberculous mycobacterial lung infection | Due to COVID-19 concerns, company closed enrolled in phase IIa Encore study | 5/8/20 |
| Savara Inc., of Austin, Texas | Molgradex | Nontuberculous mycobacterial lung infection in patients with cystic fibrosis | Stopping Encore study due to impact of COVID-19 on recruitment and continued participation as well as the impact of the approval of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor, Vertex Pharmaceuticals Inc.) | 9/3/20 |
| Scholar Rock Inc., of Cambridge, Mass. | SRK-015 | Spinal muscular atrophy | COVID-19-related restrictions have impacted patient access sites in Topaz trial, which have led to missed or delayed doses or assessments in some patients and affected ability to monitor trial data collected by sites; interim data now expected in fourth quarter of 2020, roughly a 1-month delay to previous guidance | 5/7/20 |
| Sensorion, of Montpelier, France | SENS-401 (arazasetron) | Sudden sensorineural hearing loss | Due to the reprioritization of emergency room resources due to COVID-19, the phase II Audible-S trial is recruiting patients at a slower pace than expected; company has revised its estimate for top-line data readout to mid-year 2021 | 3/13/20 |
| Seres Therapeutics Inc., of Cambridge, Mass. | SER-109 | Clostridium difficile infection | Completed enrollment of Ecospor III trial at 181 individuals with recurrent disease; enrollment halted prior to expected 188 participants due to COVID-19 pandemic; top-line results expected in mid-2020 | 3/30/20 |
| Seres Therapeutics Inc., of Cambridge, Mass. | SER-287 | Ulcerative colitis | Phase IIb study about 60% enrolled based on 201-patient target size but development adversely affected by clinical sites halting non-essential procedures, including endoscopies, due to COVID-19; trial may not achieve original enrollment target in second half of 2020 | 3/30/20 |
| Seres Therapeutics Inc., of Cambridge, Mass. | SER-401 | Metastatic melanoma | Enrollment voluntarily discontinued due to impact of COVID-19 pandemic; 10 participants currently enrolled will complete study protocol but additional development deprioritized | 3/8/21 |
| Silence Therapeutics plc, of London | SLN-124 | Beta-thalassemia or myelodysplastic syndromes | Study stopped prior to first administered dose due to COVID-19 | 4/27/20 |
| Sojournix Inc., of Waltham, Mass. | SJX-653 | Vasomotor symptoms | Enrollment of postmenopausal women halted due to COVID-19 | 4/21/20 |
| Spark Therapeutics Inc., of Philadelphia, a member of the Roche Group | SPK-3006 | Late-onset Pompe disease | Phase I/II study suspended until further notice due to COVID-19 | 5/18/20 |
| Sun Biopharma Inc., of Minneapolis | SBP-101 | Pancreatic cancer | Enrollment paused in the phase I trial of the caspase-3 stimulator due to COVID-19 pandemic in ongoing dose-escalation and expansion combination study with nab-paclitaxel and gemcitabine; currently enrolled participants will remain on treatment | 4/6/20 |
| Synairgen plc, of Southampton, U.K. | SNG-001 (inhaled formulation of interferon-beta-1a) | Chronic obstructive pulmonary disease | With 109 out of a target 120 participants already dosed in a phase II study, the trial has been paused to minimize infection risk and the distraction of respiratory staff needed for patients with COVID-19; company received approval from the Medicines and Healthcare products Regulatory Agency and Health Research Authority to conduct a trial of SNG-001 in COVID-19 | 3/18/20 |
| Syncona Ltd., of London | Various drugs | Various indications | The life sciences investor said its firms have made or are considering appropriate plans for delays of up to three months to clinical trials due to COVID-19 | 3/23/20 |
| Synlogic Inc., of Cambridge, Mass. | SYNB-1618 | Phenylketonuria | Trial enrollment delayed due to COVID-19 outbreak | 3/30/20 |
| T3D Therapeutics Inc., of Research Triangle Park, N.C. | T3D-959 | Alzheimer’s disease | Study suspended due to COVID-19 | 6/23/20 |
| Taiho Oncology Inc., of Princeton, N.J. | TAS-102 in combination with temozolomide | Metastatic pancreatic neuroendocrine tumors | Phase I study suspended due to COVID-19 | 3/25/20 |
| TC Biopharm Ltd, of Glasgow, U.K. | TCB-002 | Acute myeloid leukemia | Recruitment suspended due to COVID-19 pandemic | 4/24/20 |
| Tersera Therapeutics LLC, of Lake Forest, Ill. | Rolapitant | Malignant glioma | Trial testing drug as antiemetic following radiotherapy and temozolomide suspended due to COVID-19 | 4/22/20 |
| Tetra Bio-Pharma Inc., of Ottawa | Caumz | Cancer pain | Serenity and Reborn activities are being slowed by COVID-19; the phase III Serenity study is testing the cannabinoid drug in advanced cancer pain, while Reborn is a phase II program testing Caumz vs. fentanyl in breakthrough pain in cancer patients | 3/23/20 |
| Theralase Technologies Inc., of Toronto | TLD-1433 | Non-muscle invasive bladder cancer | Enrollment of new patients and conducting the first treatment procedure in the Phase II study has been temporarily placed on holding due to the COVID-19 pandemic | 3/20/20 |
| Theravance Biopharma Inc., of Dublin | Ampreloxetine (TD-9855) | Symptomatic neurogenic orthostatic hypertension | Data from 4-week Sequoia trial originally planned for late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19 | 5/6/20 |
| Theravance Biopharma Inc., of Dublin | TD-1473 | Ulcerative colitis | Data from phase IIb portion of phase IIb/III Rhea maintenance study originally planned for late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19 | 5/6/20 |
| Theravance Biopharma Inc., of Dublin | TD-1473 | Crohn’s disease | Data from Dione study originally planned in late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19 | 5/6/20 |
| Translate Bio Inc., of Lexington, Mass. | MRT-5005 | Cystic fibrosis | Company anticipates related interruptions in enrollment, dosing and follow-up due to COVID-19; MRT-5005 is an inhaled mRNA therapeutic | 3/27/20 |
| Trillium Therapeutics Inc., of Cambridge, Mass. | TTI-621 | Hematologic cancers and solid tumors | First participant in 1.4-mg/kg cohort dosed and on therapy; slowdown or pause in enrollment expected due to COVID-19 pandemic; TTI-621 is a CD47 antagonist | 4/8/20 |
| Trillium Therapeutics Inc., of Cambridge, Mass. | TTI-622 | Hematologic cancer | First participant in 8-mg/kg cohort dosed and on therapy; slowdown or pause in enrollment expected due to COVID-19 pandemic; TTI-622 is a CD47 antagonist | 4/8/20 |
| UCB Biopharma SPRL, of Brussels, Belgium | Cimzia (certolizumab pegol) | Moderate to severe chronic plaque psoriasis | Recruitment temporarily halted as a precautionary measure due to the COVID-19 pandemic | 4/17/20 |
| UCB Biopharma SPRL, of Brussels, Belgium | UCB-0107 | Progressive supranuclear palsy | Recruitment of phase I trial temporarily halted due to COVID-19 | 4/13/20 |
| UCB SA, of Brussels | Brivaracetam | Electroencephalographic neonatal seizures | Recruitment temporarily halted due to COVID-19 pandemic | 4/17/20 |
| UCB SA, of Brussels | Bimekizumab | Active psoriatic arthritis | Suspended enrollment in Be Optimal trial due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Bimekizumab | Active ankylosing spondylitis | Recruitment in Be Mobile 2 trial suspended due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Bimekizumab | Active nonradiographic axial spondyloarthritis | Recruitment in Be Mobile 1 trial suspended due to COVID-19 | 4/22/20 |
| UCB SA, of Brussels | Bimekizumab | Autoinflammatory disease | Suspended enrollment of healthy participants due to COVID-19 | 4/21/20 |
| UCB SA, of Brussels | Brivaracetam | Epilepsy | Enrollment in study testing drug in patients, ages 1 month to < 16 years halted due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Padsevonil | Epilepsy | Suspended study testing interaction with ethanol or cannabidiol due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Padsevonil | Epilepsy | Suspended trial testing drug in patients with normal or moderately impaired hepatic function due to COVID-19 | 4/21/20 |
| UCB SA, of Brussels | Rozanolixizumab | Chronic inflammatory demyelinating polyradiculoneuropathy | Suspended MyCIDPchoice study due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Rozanolixizumab | Generalized myasthenia gravis | Recruitment suspended due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | Rozanolixizumab | Persistent or chronic primary immune thrombocytopenia | Recruitment in MyopportunITy1 trial suspended due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels | UCB-7858 | Kidney transplant | Halted enrollment of patients with chronic allograft injury due to COVID-19 | 4/20/20 |
| UCB SA, of Brussels, Belgium | Bimekizumab | Active psoriatic arthritis | Study recruitment has been temporarily halted as a precautionary measure due to the COVID-19 pandemic | 4/24/20 |
| Uniqure NV, of Lexington, Mass., and Amsterdam) | AMT-130 | Huntington's disease | Postponing procedures of the first two enrolled patients in the Phase I/II trial due to the impact of COVID-19 | 3/26/20 |
| United Therapeutics Corp., of Silver Spring, Md. | Orenipro (treprostinil diolamine prodrug) | Pulmonary artery hypertension | Enrollment paused due to COVID-19 epidemic | 4/29/20 |
| United Therapeutics Corp., of Silver Spring, Md. | Ralinepag | Pulmonary artery hypertension | Due to COVID-19 pandemic, enrollment paused in Advance Outcomes and Advance Capacity studies | 4/29/20 |
| United Therapeutics Corp., of Silver Spring, Md. | Treprostinil (inhaled) | Pulmonary hypertension | Due to COVID-19 pandemic, enrollment paused in Sapphire study in individuals with pulmonary hypertension due to sarcoidosis | 4/29/20 |
| United Therapeutics Corp., of Silver Spring, Md. | Treprostinil Technosphere (inhaled) | Pulmonary artery hypertension | Enrollment paused in phase Ib Breeze and pivotal pharmacokinetics studies due to COVID-19 epidemic | 4/29/20 |
| United Therapeutics Corp., of Silver Spring, Md. | Tyvaso (inhaled sustained-release treprostinil) | Pulmonary hypertension | Due to COVID-19 pandemic, enrollment paused in Perfect open-label extension study in individuals with pulmonary hypertension due to chronic obstructive pulmonary disease | 4/29/20 |
| US Worldmeds LLC, of Louisville, Ky. | Lucemyra | Opioid withdrawal | Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic | 4/10/20 |
| Vaccinex Inc., of Rochester, N.Y. | Pepinemab | Huntington’s disease | Despite delayed assessments on 2 participants due to COVID-19 pandemic, potentially pivotal Signal trial expected to complete as expected, with database lock by September 2020 and top-line data potentially by early October 2020; following FDA input, efficacy results for 265 enrolled participants will be analyzed in 2 groups: co-primary endpoints for first group (n=179) diagnosed with early manifest disease are Clinical Global Impression of Change from baseline through 18 months of treatment and selected cognitive assessments from Huntington’s Disease Cognitive Assessment Battery; single primary endpoint for second group of all participants, representing continuum of disease, is Total Functional Capacity | 7/7/20 |
| Valneva SE, of Saint, Herblain, France | VLA-1533 | Chikungunya | Company is preparing for phase III initiation as soon as the COVID-19 situation permits and potentially in the fourth quarter of 2020 | 3/25/20 |
| Veloxis Pharmaceuticals A/S, of Copenhagen | Envarsus XR (tacrolimus extended-release tablets) | Simultaneous kidney and pancreas transplantation | Recruitment suspended due to COVID-19 pandemic | 4/17/20 |
| Venatorx Pharmaceuticals Inc., of Malvern, Pa. | VNRX-5024 | Bacterial infection | Trial in healthy adult volunteers suspended due to COVID-19 | 5/15/20 |
| Venatorx Pharmaceuticals Inc., of Malvern, Pa. | VNRX-5024 | Healthy subjects | Recruitment of phase I trial temporarily suspended due to COVID-19 | 4/9/20 |
| Venatorx Pharmaceuticals Inc., of Malvern, Pa. | VNRX-7145 | Healthy subjects | Phase I study enrollement suspended due to COVID-19 | 3/26/20 |
| Verona Pharma plc, of London | Ensifentrine (pressurized metered-dose inhaler) | Chronic obstructive pulmonary disease | Enrollment in part B of its phase II trial delayed due to COVID-19 pandemic | 3/31/20 |
| Vertex Inc., of Boston | VX-814 | Alpha-1 antitrypsin deficiency | Temporarily paused screening and enrollment due to COVID-19 | 4/29/20 |
| Vertex Pharmaceuticals Inc., of Boston | Various drugs | Various indications | Working with clinical trial sites to enable virtual visits and home delivery of study drugs, but is temporarily pausing enrollment in certain studies and may delay some new study starts | 3/27/20 |
| Wize Pharma Inc., of Hod Hasharon, Israel | LO2A | Dry eye syndrome in patients with Sjögren's syndrome | Completed dosing of patients in the study; top-line data release may be delayed into third fiscal quarter of 2020 due to COVID-19 | 5/7/20 |
| X4 Pharmaceuticals Inc., of Cambridge, Mass. | Mavorixafor | WHIM syndrome | Timing of top-line data release delayed from second half of 2021 to 2022 due to COVID-19 | 5/7/20 |
| Xbrane Biopharma AB, of Solna, Sweden | Xlucane | Wet age-related macular degeneration | Xplore study remains open with 355 of 580 patients enrolled, but COVID-19 makes forecasting future recruitment rate challenging; Biosimilar of Lucentis (ranibizumab) | 4/2/20 |
| Xenon Pharmaceuticals Inc., of Burnaby, British Columbia | XEN-1101 | Focal epilepsy | X-Tole phase IIb trial is experiencing a significant reduction in new patient enrollment due to COVID-19; top-line data is now expected in the first half of 2021 | 3/31/20 |